As part of its advocacy program in the United States, ACRO submits regulatory comments to U.S. regulators. This comment response, submitted by ACRO to the FDA in September 2026 on the revised draft guidance demonstrating substantial evidence of effectiveness for human drug and biological products, can be found below.